Effect and Safety of Menatetrenone on Treatment of Postmenopausal Osteoporosis.

Trial Profile

Effect and Safety of Menatetrenone on Treatment of Postmenopausal Osteoporosis.

Completed
Phase of Trial: Phase III

Latest Information Update: 23 Apr 2013

At a glance

  • Drugs Menatetrenone (Primary) ; Alfacalcidol
  • Indications Postmenopausal osteoporosis
  • Focus Therapeutic Use
  • Sponsors Eisai Co Ltd
  • Most Recent Events

    • 07 Jun 2017 Biomarkers information updated
    • 22 Dec 2009 Actual number of patients (240) added as reported by ClinicalTrials.gov.
    • 22 Dec 2009 Actual end date (Jan 2007) added as reported by ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top